Acetylcholine Receptor Blocking Ab, Serum

Additional Info: Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR blocking autoantibodies prevent interaction of binding antibodies with the AChR. Fewer than 1% of patients have blocking antibodies without binding antibodies. Blocking antibodies are present in about 50% of patients with MG, but rare in other conditions. Therefore, blocking antibodies have utility in ruling out a possible false positive binding assay and detecting the rare patient without AChR binding antibodies.

Methodology: Radioimmunoassay

Specimen Requirements:

1 yellow-top SST tube (minimum: 0.5 mL of serum). Centrifuge SST 30 minutes after draw. Refrigerate specimen after collection.

Analytical Time:

2 days

Days Set Up: Sunday through Friday

CPT Information:
83519 –